Goldman Sachs Lowers Estimates on Illumina, But Favors MiSeq Growth Over PGM
June 24, 2011
Goldman Sachs Lowers Estimates on Illumina, But Favors MiSeq Growth Over PGM
The investment firm lowered EPS estimates for Illumina on an expected shift to the MiSeq platform from the HiSeq system, but said that in a short amount of time Illumina's desktop sequencer would overtake Ion Torrent's PGM as the market leader.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Analysts Increase Valuations, Upgrade Illumina
January 4, 2013 / GenomeWeb Daily News - Researchers Rank MiSeq over PGM for Usability; Expect Their Sequencing Output to Grow by Half in 2013
January 22, 2013 / In Sequence - BGI Reviews Next-Gen Sequencing Platforms, Highlighting Advantages of Each System
August 14, 2012 / In Sequence - Leerink Swann Upgrades Illumina; Revises Estimates for Life Tech, Thermo Fisher, Others
July 23, 2012 / GenomeWeb Daily News - Survey Finds MiSeq, Ion PGM Tied for Most Likely Sequencing Purchase over Next 12 Months
April 24, 2012 / In Sequence